Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Denovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma
Details : Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.
Brand Name : DB102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Rumpus Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).
Brand Name : AR101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 12, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Rumpus Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Recipient : Neos Therapeutics
Deal Size : $44.9 million
Deal Type : Merger
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement
Details : Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.
Brand Name : Cotempla XR-ODT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Recipient : Neos Therapeutics
Deal Size : $44.9 million
Deal Type : Merger
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and will be able to be commercialized and supplied within Australia.
Brand Name : Zolpimist
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 30, 2020
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?